Navigation Links
Aethlon Medical Introduces HER2osome™, A Novel Therapeutic Device Strategy to Address Breast Cancer
Date:9/21/2011

SAN DIEGO, Sept. 21, 2011 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today the introduction of HER2osome™, a novel medical device strategy to inhibit the progression of HER2+ breast cancer, which is characterized by aggressive growth and poor prognosis resulting from the over-expression of HER2 protein.  Breast cancer represents the most common form of invasive cancer in women. HER2+ breast cancer accounts for approximately 25% of new breast cancer diagnosis.

(Photo:  http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b)

The goal of HER2osome™ therapy is to simultaneously reduce the circulatory presence of HER2 protein and breast cancer exosomes, which have increasingly become recognized as playing pivotal role in the development and progression of breast cancer.  Researchers report that breast cancer exosomes suppress the immune response, stimulate angiogenesis, contribute to the spread of metastasis, and inhibit the therapeutic benefit of Herceptin (trastuzumab), a leading monoclonal antibody treatment against the HER2+ breast cancer.  As an adjunct therapeutic candidate, HER2osome™ offers to address an unmet medical need and enhance the benefit of Herceptin and standard of care chemotherapies without adding drug toxicity or interaction risks.  

To support the pre-clinical and clinical advancement of HER2osome™, Aethlon has submitted a funding proposal entitled, "An Innovative Device Strategy to Eliminate HER2 Breast Cancer Progression" to the Breast Cancer Research Program (BCRP) offered through the Assistant Secretary of Defense for Health Affairs, Defense Health Program. The BCRP was established in fiscal year 1992 (FY92) to support innovative research focused on eradicating breast cancer. Appropr
'/>"/>

SOURCE Aethlon Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Aethlon Medical to Present at the 2009 RedChip Small-Cap Investor Conference on June 16, 2009
2. Aethlon Medical Announces Presentation of Hepatitis-C (HCV) Clinical Data at 42nd Annual American Society of Nephrology (ASN) Conference
3. Aethlon Medical Releases Medical Device Data Against the H1N1 Swine Flu Virus
4. Aethlon Medical Discloses Live Webcast of Todays BIOCOM Presentation
5. Aethlon Medical Announces Expansion of Hepatitis C Virus (HCV) Treatment Programs
6. Aethlon Medical Announces Approval of Hepatitis C Virus (HCV) Treatment Program
7. Aethlon Medical to Present at Rodman & Renshaw Annual Global Investment Conference
8. Aethlon Medical Reestablishes Biodefense Programs
9. Aethlon Medical Engages Fabiani & Company to Advance U.S. Government Partnerships
10. Aethlon Medical Announces Appointment of Rod Kenley to Its Board of Directors
11. Aethlon Medical Names Rod Kenley President
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 AARP Foundation ... to support older adults suffering from the severe ... AARP and its members are committed to helping those ... AARP and AARP Foundation will match dollar-for-dollar contributions up ... aid. The matching program will be administered through AARP ...
(Date:1/15/2014)... LAWRENCEVILLE, N.J. , Jan. 15, 2014  Celsion ... today announced that it has received commitments from ... $15 million of the Company,s common stock in ... dedicated health care fund. The Company ... pursuant to which the Company agreed to sell ...
(Date:1/15/2014)... 15, 2014 Shire plc (LSE: SHP, ... the Office of Fair Trading (OFT) approval condition to the ... ViroPharma Incorporated (NASDAQ: VPHM).   As a result ... OFT approval, and Shire expects to complete the tender offer ... subject to the satisfaction of all of the remaining conditions ...
Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
... 2011 PDI, Inc. (Nasdaq: PDII ), a ... companies, today announced the extension of a contract sales engagement ... began April 1 and will run for the balance of ... PDI of approximately $23 million. Under the program, ...
... April 4, 2011 VIVUS, Inc. (Nasdaq: VVUS ... the investigational drug QNEXA® for two years showed reductions in ... as improvements in lipid levels following significant reductions in weight ... two years. The data – additional results ...
Cached Medicine Technology:PDI Announces Contract Extension With Revenue Value of Approximately $23 Million 2Weight Loss With QNEXA® Over Two Years Provides Patients With Substantial Cardiovascular Benefits 2Weight Loss With QNEXA® Over Two Years Provides Patients With Substantial Cardiovascular Benefits 3
(Date:4/14/2014)... A new study identifies a molecule that is a ... the molecule could be an important target for colorectal ... , The study of microRNA-135b (miR-135b) in two animal ... Cancer Cell and was led by researchers ... Arthur G. James Cancer Hospital and Richard J. Solove ...
(Date:4/14/2014)... 14In dense, urban centers around the world, many people ... by tall buildings that block sunlight. And as the ... closer together, the darkness will only spread. , ... corrugated, translucent panel that redirects sunlight onto narrow streets ... hung over the edge at an angle, where it ...
(Date:4/14/2014)... Using antibiotics alone to treat children with uncomplicated acute ... to less pain and fewer missed school days, according ... team at Nationwide Children,s Hospital and published online April ... of Surgeons , is the first prospective study on ... the United States. , Researchers enrolled 77 patients ...
(Date:4/14/2014)... it comes to the cost and quality of hospital ... best care when they are treated in units that ... their current job, according to a study from researchers ... School. The study was published in the current issue ... , The review of more than 900,000 patient ...
(Date:4/11/2014)... insights into the processes that control brain cell production ... and other brain-related disorders. , Scientists have gained new ... that controls how and when nerve and brain cells ... to develop and keeps it healthy. Their findings could ... of control, which is a fundamental characteristic of many ...
Breaking Medicine News(10 mins):Health News:Study identifies a likely key driver of colorectal cancer development and progression 2Health News:Let the sun shine in: Redirecting sunlight to urban alleyways 2Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 2Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 3Health News:Longer nurse tenure on hospital units leads to higher quality care 2
... ... ... ... ...
... ... CyberKnife patients in February 2010, , ... Chicago (PRWEB) February 22, 2010 -- Accelitech LLC ... New Brunswick, NJ, a hospital-based facility operated by Saint Peter’s University Hospital. The ...
... ... ... , ... AAPA honors U.S. Surgeon General Regina Benjamin for commitment to patient care , ...
... ... of the RDX storage technology include industry leaders Dell, Fujitsu, Hitachi, HP, IBM, Imation, Maxell, ... ... announced that Maxell , a technology and marketing leader in premium data storage media ...
... ... proudly offer lead commission on submitted and completed applications as well as multiple tiers of ... advertising partner today and start earning some of the highest affiliate commissions in the financial ... Orem, UT ...
... ... create an opportunity for millions of PowerPoint and Keynote users to up their game ... Santa Clara, ... Ed Kaim unveiled SpeakFlow™, a suite of tools for creating, managing, and delivering non-linear ...
Cached Medicine News:Health News:AppDynamics Announces General Availability of AppDynamics v2.0 2Health News:AppDynamics Announces General Availability of AppDynamics v2.0 3Health News:AppDynamics Announces General Availability of AppDynamics v2.0 4Health News:AppDynamics Announces General Availability of AppDynamics v2.0 5Health News:AppDynamics Announces General Availability of AppDynamics v2.0 6Health News:AppDynamics Announces General Availability of AppDynamics v2.0 7Health News:AppDynamics Announces General Availability of AppDynamics v2.0 8Health News:AppDynamics Announces General Availability of AppDynamics v2.0 9Health News:Accelitech's 2nd New Jersey CyberKnife Site Commences Operations 2Health News:Physician Assistants Call on Congress for Policies That Promote High-Quality Patient Care 2Health News:Physician Assistants Call on Congress for Policies That Promote High-Quality Patient Care 3Health News:Maxell Joins RDX Storage Alliance to Support Growing Storage Professionals' Community 2Health News:Maxell Joins RDX Storage Alliance to Support Growing Storage Professionals' Community 3Health News:Check City Announces New Payday Affiliate Campaign Through Partnership With The Share A Sale Affiliate Network 2Health News:Check City Announces New Payday Affiliate Campaign Through Partnership With The Share A Sale Affiliate Network 3Health News:SharpLogic Announces Launch Of SpeakFlow Non-Linear Presentation Suite At SpeakFlow.com 2Health News:SharpLogic Announces Launch Of SpeakFlow Non-Linear Presentation Suite At SpeakFlow.com 3
... insulin pen with a memory. HumaPen MEMOIR records the ... (including priming doses). You can see exactly when and ... you simply "dial" your dose by turning the dose ... initial set-up. If you dial too many units, you ...
Assay development using client's antibodies and antigens to meet diagnostic target...
Colloidal Gold Conjugated, Streptavidin - 50 OD...
Colloidal Gold Conjugated, Goat anti-rabbit IgG (H&L) - 50 OD...
Medicine Products: